Access to Information Requests Completed - July 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

Completed Requests

For the month of July 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2009-01312	All documents relating to application for licenses for sea lice pest management on Southern New Brunswick Salmon Aquiculture sites. (Jan 1, 2009 to Dec 31, 2009).	Disclosed in part	1,835
A-2010-00044	All documents created dealing with asbestos related disease. (Nov 1, 2009 to Apr 12, 2010).	Disclosed in part	723
A-2010-00509	Information regarding the product HP-PAC (amoxicillin / clarithromycin / lansoprazole) by TAKEDA PHARMACEUTICALS AMERICA INC.	Disclosed in part	188
A-2010-00670	Information regarding the product ANDROGEL by Abbot Products Inc.	Disclosed in part	127
A-2010-00910	All documents concerning the genesis, development, creative approval, and final; authorizations to release for broadcast regarding the television advertisement that was broadcast on November 22, 2010 by, or on behalf of, the Government of Canada regarding childhood obesity and high-calorie foods, including sugar-sweetened drinks or similarly-described beverages. (Nov 26, 2009 to Nov 25, 2010).	Disclosed in part	527
A-2010-00911	All documents concerning any advertising campaign or plan associated with the television advertisement that was broadcast on November 22, 2010 by, or on behalf of, the Government of Canada regarding childhood obesity and high-calorie foods, including sugar-sweetened drinks or similarly-described beverages. (Nov 23, 2009 to Nov 23, 2010).	Disclosed in part	348
A-2010-01195	All documents from 2010 relating to the commitment to "consider requesting more comprehensive project information from Infoway in order to obtain sufficient level of assurance that grant installments are based on clearly defined projects with specific expenditure commitments and timelines".	Disclosed in part	236
A-2010-01196	All documents from 2010 relating to the commitment to "obtain information from Infoway that will further support its annual cash flow requests - namely, information to support verification that funds requested are closely aligned with project requirements, and that they are based on Infoway's obligations".	Disclosed in part	236
A-2010-01197	All documents from 2010 relating to the commitment to "continue to monitor Infoway's use of funds to gauge compliance with the intended purposes of the funds".	Disclosed in part	263
A-2010-01380	All documents pertaining to H.J. Heinz Company of Canada Ltd cereal products and all relevant documents pertaining to infant botulism. (Jan 1, 2006 to Feb 28, 2011).	Disclosed in part	377
A-2010-01558	Information regarding the product Clindamycin Phosphate Injection USP Liq, DIN 02051826 by Lyphomed, Division of Fujisawa Canada Inc.	All exempted	0
A-2011-00089	All documents concerning the studies conducted in 2001 and 2005/2006 in the custody of Occupational Health Clinic having to do with Simian Foamy Virus testing/retesting.	Disclosed in part	1,155
A-2011-00236	Information regarding the product Advil Cold and Sinus Daytime, DIN 02267616 by Pfizer Consumer Healthcare, a division of Pfizer Canada Inc.	Disclosed in part	340
A-2011-00535	AERs for the product Tylenol. Report numbers: 000332949, 000334206, 000334280, 000336406, 000336529, 000340356, 000343404, 000343686, 000343743 and 000343745.	Disclosed in part	95
A-2011-00537	AERs for the product Benylin. Report numbers: 000122414, 000127702, 000137640, 000139235, 000169067, 000171674, 000173444, 000173828, 000174241 and 000186672.	Disclosed in part	77
A-2011-00649	All documents related to the meeting/communication involving representatives from the Canadian Generic Pharmaceutical Association (CGPA), Sandoz Canada Inc., Sarah Wiles and Paul Glover on June 21, 2011.	All disclosed	79
A-2011-00833	All relevant documents produced during 2011 regarding discussions and internal and inter-agency correspondence regarding the Supreme Court of Canada case considering the ability of the federal government to close Insite.	Disclosed in part	150
A-2011-00842	Documents which pertain to 'compassion club', 'cannabis club', 'compassion centre', or 'compassion society'. (Jan 1, 2001 to Sep 30, 2011).	Disclosed in part	138
A-2011-01344	All documents relating to prebiotics and probiotics in infant formula with the following brand name: Parent's Choice. (Jan 1, 2008 to Jan 17, 2012).	Disclosed in part	99
A-2011-01345	All documents relating to prebiotics and probiotics in infant formula with the following brand name: President's Choice. (Jan 1, 2008 to Jan 16, 2012).	Disclosed in part	99
A-2011-01380	Information regarding the medical device PULMONARY VEIN ABLATION CATHETER (PVAC), License number 83462.	Disclosed in part	461
A-2011-01428	Information regarding the product Remicade by JANSSEN INC.	Disclosed in part	313
A-2011-01445	Information regarding the product Genestra Brands™ Tad+, NPN 00554472 by Seroyal International.	Disclosed in part	103
A-2011-01488	Minutes and agendas at headquarters about the Food Regulatory Advisory Committee. (Feb 8, 2011 to Feb 1, 2012).	Disclosed in part	635
A-2011-01495	All documentation between J. Rettenmaier USA LP and Health Canada supporting the request for and Health Canada's approval of Vitacel HF301CA Oat Fibre.	Disclosed in part	169
A-2011-01544	Information regarding the depersonalized production license revocation of Legal marijuana production (medical). (Feb 15, 2007 to Feb 14, 2012).	Disclosed in part	150
A-2011-01572	Inspections and final report for "All types of kitchen utensils and tools imported from China; the statistics as proposed in your suggestion should do". (Jan 1, 2009 to Feb 16, 2012).	Disclosed in part	64
A-2011-01611	AERs for the product Indapamide. Report numbers: 000352938, 000352631, 000353234, 000354724, 000355976 and 000359517.	Disclosed in part	12
A-2011-01625	Information regarding the product Drixoral Decongestant Nasal Spray 0.05%, DIN 00740861.	Disclosed in part	72
A-2011-01626	Information regarding the product Drixoral No Drip, DIN 02362236.	Disclosed in part	35
A-2011-01629	Information regarding the product Drixoral No Drip With Cooling Menthol, DIN 02245580.	Disclosed in part	113
A-2011-01695	Information regarding the product Holy Basil, NPN 80024741 by St. Francis Herb Farm Incorporated.	Disclosed in part	101
A-2012-00044	AERs for the product Tecta (Pantoprazole Maggnesium). Report numbers: 000380956, 000381299, 000382785, 000383716, 000386089, 000386239, 000387222, 000392363 and 000396345.	Disclosed in part	21
A-2012-00091	Copy of the reports issued by Health Canada following routine inspections of the Boucherville, QC plant of Sandoz, division of Novartis.	Disclosed in part	15
A-2012-00104	AERs for the product Cipralex. Report numbers: 000381288, 000382459, 000382484, 000384892, 000391057 and 000396693.	Disclosed in part	16
A-2012-00105	AERs for the product Celexa. Report numbers: 000381764, 000387270, 000394569 and 000394585.	Disclosed in part	7
A-2012-00106	AER for the product Cosmegen. Report number: 000387899.	Disclosed in part	3
A-2012-00163	Information about Health Canada's Report on Annual expenditures for travel, hospitality and conferences for fiscal year 2010-2011.	All disclosed	4
A-2012-00164	All documents about Johnson & Johnson and Schedule F of the Food and Drugs Act. (Jun 1 2011 to May 1 2012).	No records exist	0
A-2012-00170	Hazardous Situation Report concerning name confusion between 'Tactuo and Toctino'.	Disclosed in part	3
A-2012-00171	Product Monograph for the product Accutane (Isotretinoin).	All disclosed	564
A-2012-00177	Product Monograph for the product Apo-Norflox.	All disclosed	49
A-2012-00205	User Manual for MiniArc Sling System. (Jan 1, 1996 to May 7, 2012).	All disclosed	99
A-2012-00207	All documents related to potential safety risk with respect to the Monarc Subfascial Hammock. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	83
A-2012-00263	User Manual for GYNECARE PROLIFT +M Pelvic Floor Repair System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	12
A-2012-00310	Question period briefing notes provided to the Minister of Health Leona Aglukkaq. (May 14-18, 2012).	Disclosed in part	72
A-2012-00313	List of briefing notes and memorandums that were sent to or created for the federal Health Minister. (May 1, 2012 to May 26, 2012).	Disclosed in part	7
A-2012-00344	Dental and Oral Care Products for Professional Use: Labelling Standard.	All disclosed	9
A-2012-00345	Dietary Mineral Supplements: Category IV Monograph.	All disclosed	11
A-2012-00347	Echinacea: Labelling Standard.	All disclosed	4
A-2012-00348	Ephedrine/Pseudoephedrine: Labelling Standard.	All disclosed	4
A-2012-00349	Feverfew Leaf: Labelling Standard.	All disclosed	3
A-2012-00350	Hydrocortisone (tropical): Labelling Standard.	All disclosed	4
A-2012-00351	Laxatives: Carbon Dioxide Releasing: Labelling Standard.	All disclosed	2
A-2012-00353	Laxatives Hyperosmotic: Labelling Standard.	All disclosed	2
A-2012-00354	Laxatives : Saline: Labelling Standard.	All disclosed	4
A-2012-00355	Medicated Skin Care Products: Category IV Monograph.	All disclosed	4
A-2012-00356	Mineral Supplements: Labelling Standard.	All disclosed	29
A-2012-00357	Nicotine Gum: Labelling Standard.	All disclosed	10
A-2012-00358	Nicotine Patches: Labelling Standard.	All disclosed	10
A-2012-00359	Oral Potassium Supplements: Labelling Standard.	All disclosed	4
A-2012-00360	Peppermint: Labelling Standard.	All disclosed	5
A-2012-00362	Peroxide Oral Care: Labelling Standard.	All disclosed	6
A-2012-00364	Sunburn protectants: Category IV Monograph.	All disclosed	14
A-2012-00365	Throat Lozenges: Category IV Monograph.	All disclosed	6
A-2012-00366	Ubiquinone: Labelling Standard.	All disclosed	2
A-2012-00367	Valerian: Labelling Standard.	All disclosed	4
A-2012-00368	Vitamin Supplements: Labelling Standard.	All disclosed	24
A-2012-00380	AERs. Report numbers: 000389934, 000397842, 000404343, 000353332 and 000333365.	Disclosed in part	9
A-2012-00381	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of May 2012.	Disclosed in part	53
A-2012-00382	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during May 2012.	All disclosed	2
A-2012-00383	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of May 2012.	Disclosed in part	12
A-2012-00388	AER for the product Cipro. Report number: 000395345.	Disclosed in part	2
A-2012-00389	AER for the product Kogenate FS. Report number: 000394852.	Disclosed in part	3
A-2012-00390	AER for the product Magnevist. Report number: 000391763.	Disclosed in part	1
A-2012-00391	AERs for the product Gadovist. Report numbers: 000391791 and 000395977.	Disclosed in part	2
A-2012-00392	AERs for the product Mirena. Report numbers: 000385306 and 000385538.	Disclosed in part	2
A-2012-00393	AERs for the product Xarelto. Report numbers: 000394425 and 000396142.	Disclosed in part	4
A-2012-00395	AER for the product Yaz. Report number: 000393478.	Disclosed in part	1
A-2012-00405	Meeting minutes from the meeting of the Scientific Advisory Committee on Non-prescription Drugs held May 10, 2012, pertaining to acne products.	All exempted	0
A-2012-00408	Information regarding the product Lovenox, DIN 02012472) by Sanofi-Aventis Canada Inc.	Disclosed in part	36
A-2012-00410	All documents regarding Tobacco Recovery Lawyers LLP. (Jan 1, 2010 to Jun 13, 2012).	No records exist	0
A-2012-00417	Department's communication strategy and guideline specifically how it has been ordered or decided to deal with media request (Example: Request to interview scientists about studies).	All disclosed	4
A-2012-00418	All documents concerning sterilization (including forced sterilization). (Jan 1, 2007 to Jun 19, 2012).	No records exist	0
A-2012-00424	All documents that relate to any communications, regarding wind turbines, between Health Canada and the following organisations: Stantec Consulting Ltd, Intrinsik Environmental Science Inc. (Jan 1, 2009 to Jun 15, 2012).	Disclosed in part	30
A-2012-00425	Product Monograph for the product Novo-Norfloxacin, DIN 02237682.	All disclosed	112
A-2012-00426	Product Monograph for the product Apo-Norfloxacin, DIN 02091208.	All disclosed	50
A-2012-00430	Copy of the drafts and final version of David Michaud's paper on wind turbines being presented at the Noise Conference 2012, New-York City, NY.	All disclosed	15
A-2012-00434	Product Monograph for the product Levofloxacin.	All disclosed	1,154
A-2012-00438	Product Monograph for the product Ratio-Ciprofloxacin, DINs 02246825, 02246826 and 02246827.	All disclosed	177
A-2012-00439	A listing of the Access to Information requests submitted to Health Canada. (May 1, 2012 to May 31, 2012).	Disclosed in part	13
A-2012-00453	Documents which indicate names of officials who are authorized to request translation services from third party suppliers in the National Capital Region and purchase order or other document that requests the translation service. (Jan 1, 2012 to May 31, 2012).	Disclosed in part	73
A-2012-00455	All call-ups processed by this institution in the Toronto region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services. (Jan 1, 2011 to Apr 30, 2012).	All disclosed	60
A-2012-00456	Information regarding the product Prochymal by Osiris Therapeutics Inc.	All exempted	0
A-2012-00458	Names and affiliations, relating to wind turbines, of the 22 individuals with expertise in areas including public health, epidemiology, statistics, acoustics, medicine and health effects of noise. (Aug 1, 2011 to Jun 29, 2012)	All disclosed	3
A-2012-00468	AER for the product Synagis AR. Report number: 000376730.	Disclosed in part	2
A-2012-00483	All documents with the Health Canada Research Ethics Board on or related to audits/inquiries/investigations/of possible conflicts of interest or non-transparent processes or misdirected or misused monies at in relation to wireless/ electromagnetic fields/ radiofrequency /cellular & mobile technologies / Safety Code 6.	No records exist	0
A-2012-00492	List of members and/or participants consulted by the research team of the health study on industrial wind turbines. (Jun 22, 2012 to Jun 27, 2012).	Disclosed in part	10
A-2012-00502	Report of losses and thefts of Oxycontin. (Jan 1, 2012 to May 31, 2012).	All disclosed	15
A-2012-00503	Report of losses and thefts of OxyNeo. (Jan 1, 2012 to May 31, 2012).	All disclosed	6
A-2012-00504	Report of losses and thefts of Hydromorph Contin. (Jan 1, 2012 to May 31, 2012).	All disclosed	5
A-2012-00505	Report of losses and thefts of Dilaudid. (Jan 1, 2012 to May 31, 2012).	All disclosed	8
A-2012-00588	Report on the Eeya-keen Healing, Winnipeg, Manitoba.	No records exist	0